Research programme: sestrin modulators - Quark PharmaceuticalsAlternative Names: Sestrin modulators research programme - Quark Pharmaceuticals
Latest Information Update: 31 Aug 2010
At a glance
- Originator Quark Biotech
- Developer Quark Pharmaceuticals
- Mechanism of Action Antioxidants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Ischaemic heart disorders
Most Recent Events
- 21 Jun 2004 Preclinical trials in Ischaemic heart disorders in USA (unspecified route)